Edward T Chang, MD, MS in Jblm, WA - Otolaryngology

Edward T Chang, MD, MS is a Otolaryngology physician based in Jblm, Washington. Edward T Chang is licensed to practice in Georgia (license number 79106) and his current practice location is 9040a Jackson Ave, Jblm, Washington. He can be reached at his office (for appointments etc.) via phone at (253) 968-1110.

NPI number for Edward T Chang is 1144581059 and his current mailing address is 9040 Jackson Ave, Tacoma, Washington. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1144581059.

Contact Information

	Edward T Chang, MD, MS
	9040a Jackson Ave, Jblm, WA 98431
	(253) 968-1110
	Not Available

Physician's Profile

Full Name	Edward T Chang
Gender	Male
Speciality	Otolaryngology
Location	9040a Jackson Ave, Jblm, Washington
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1144581059
Provider Enumeration Date: 06/06/2012
Last Update Date: 08/08/2023

Medical Identifiers

Medical identifiers for Edward T Chang such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1144581059	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207Y00000X	Otolaryngology	MD17315 (Hawaii)	Secondary
207Y00000X	Otolaryngology	79106 (Georgia)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Edward T Chang is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Edward T Chang, MD, MS 9040 Jackson Ave, Tacoma, WA 98431-0001 Ph: (253) 968-1420	Edward T Chang, MD, MS 9040a Jackson Ave, Jblm, WA 98431 Ph: (253) 968-1110

News Archive

NaturalNano nanotubes improve targeting of circulating tumor cells: Study

NaturalNano, Inc. announced today that Dr. Michael King, a researcher at Cornell University, has published a new study demonstrating how NaturalNano nanotubes can improve targeting of circulating tumor cells (CTC's). These nanotubes, when added to the surface where cancer cells are attracted, enhance the natural rolling mechanism that Dr. King believes will allow them to be exposed to specific drugs or other therapeutic agents, or isolated for diagnostic and research purposes.

PositiveID reaches chemistry milestone in glucose-sensing RFID microchip development

PositiveID Corporation announced today that it has reached an important chemistry milestone in the development of its GlucoChip, glucose-sensing RFID microchip.

Boehringer Ingelheim to acquire certain assets of Wyeth Pharmaceutical after Pfizer-Wyeth merger

Boehringer Ingelheim, a global pharmaceutical group of companies, together with its U.S. animal health business Boehringer Ingelheim Vetmedica, Inc., announced today that it has entered into an agreement with Pfizer to acquire certain assets of Wyeth Pharmaceutical's Fort Dodge Animal Health business upon the closing of the global Pfizer-Wyeth merger, which is expected to occur early in the fourth quarter.

OrSense's NBM 200MP non-invasive Hb measurement system more accurate than invasive POC devices

OrSense Ltd., developer of monitors for non-invasive measurements of various blood parameters, presented in an oral presentation at the American Society of Anesthesiologists (ASA) annual meeting in San Diego, results showing that hemoglobin (Hb) measurements obtained by its NBM 200MP, a non-invasive Hb measurement system, showed accurate performance during hemorrhage conditions compared with invasive point of care (POC) devices.

Edward T Chang, MD, MS - Otolaryngology in Jblm, WA